Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 6,767 matching trials from the live ClinicalTrials.gov search.
Filters: Bethesda, Maryland Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells

NCT00001234
View directory record Official record
Conditions
Gaucher's Disease
Interventions
human glucocerebrosidase cDNA
Genetic
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 8:19 PM EDT
Recruiting Phase 2 Interventional

Losartan to Improve Outcomes After Multi-ligament Knee Injury

NCT06933706
View directory record Official record
Conditions
Multi-ligament Knee Injury
Interventions
losartan 25 mg, Placebo capsule
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Lexington, Kentucky • Bethesda, Maryland • Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 27, 2026, 8:19 PM EDT
Terminated Phase 1 Interventional

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

NCT00973804
View directory record Official record
Conditions
Leukemia, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, MDS, Multiple Myeloma
Interventions
EPOCH-F/R, FLAG, Transplant Preparative Regimen (Flu/Cy/Mes), GVHD Prophylaxis (tacrolimus and sirolimus), Double Cord Blood Transplantation
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 27, 2026, 8:19 PM EDT
Completed No phase listed Observational

Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

NCT00923884
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, Carcinoma, Small-Cell Lung
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

NCT00193492
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Bevacizumab, Rituximab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
22
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019487
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, gp209-2M antigen, incomplete Freund's adjuvant
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 27, 2026, 8:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

NIAID Centralized Sequencing Protocol

NCT03206099
View directory record Official record
Conditions
Atopy, Primary Immunodeficiency, Autoimmunity, Autoinflammation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 100 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2042
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Not applicable Interventional Results available

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials

NCT03531814
View directory record Official record
Conditions
Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions
Medication Event Monitoring System (MEMS^TM), Questionnaires
Behavioral · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis

NCT00001614
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Uveitis
Interventions
Chicken type II collagen
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 8:19 PM EDT
Completed No phase listed Observational

Screening for Research Subjects With Anterior Segment Diseases

NCT00088348
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 8:19 PM EDT
Completed No phase listed Observational

Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease

NCT00382564
View directory record Official record
Conditions
Atherosclerosis, Hyperlipidemia, Hypertension, Diabetes Mellitus
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 27, 2026, 8:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oral Metformin for Treatment of ABCA4 Retinopathy

NCT04545736
View directory record Official record
Conditions
ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration
Interventions
Metformin hydrochloride
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 8:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Roles of Trust and Respect in Patient Reactions to Race-based and Personalized Medicine Vignettes: An Experimental Study

NCT00911833
View directory record Official record
Conditions
Diabetes, Congenital Heart Disease, Hypertension
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 8:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Flumazenil on Brain Excitability

NCT00015678
View directory record Official record
Conditions
Stroke, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 27, 2026, 8:19 PM EDT
Recruiting No phase listed Observational

Artificial Intelligence for Brain MRI Analysis in Epilepsy

NCT07881185
View directory record Official record
Conditions
Epilepsies
Interventions
Not listed
Lead sponsor
Istituto Giannina Gaslini
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

NCT00076843
View directory record Official record
Conditions
HTLV-1
Interventions
Hu MiK-Beta-1
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00682643
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
fluticasone furoate nasal spray, vehicle placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
56
States / cities
Oxford, Alabama • Little Rock, Arkansas • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravenous Norepinephrine for Orthostatic Hypotension

NCT01285908
View directory record Official record
Conditions
Orthostatic Hypertension
Interventions
Intravenous Norepinephrine Infusion
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant

NCT01431209
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions
Laboratory Biomarker Analysis, Ruxolitinib Phosphate
Other · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 27, 2026, 8:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01896999
View directory record Official record
Conditions
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
479
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 8:19 PM EDT
Terminated Phase 2 Interventional Results available

Riluzole to Treat Depression in Bipolar Disorder

NCT00054704
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Riluzole, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

NCT03507452
View directory record Official record
Conditions
Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma, Advanced Recurrent Serous Ovarian Cancer, Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)
Interventions
BAY2287411
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 27, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy

NCT00004547
View directory record Official record
Conditions
Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm
Interventions
Surgery, Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin, Postoperative dwell with paclitaxel and 5-FU
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 27, 2026, 8:19 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of the Blood Vessels of the Heart

NCT00001638
View directory record Official record
Conditions
Heart Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
2,916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 27, 2026, 8:19 PM EDT